PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 10/24/23

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Requir...

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime ...

2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings  ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...

2023-09-27 08:49:39 ET Summary Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in human cell lines, including correcting genetic causes ...

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...

2023-08-07 17:36:27 ET Prime Medicine press release ( NASDAQ: PRME ): Q2 GAAP EPS of -$0.47 misses by $0.04 . As of June 30, 2023, cash, cash equivalents, investments and restricted cash were $221.1 million, as compared to $263.0 million as of March 31, 2023. For...

-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multip...

2023-07-25 07:45:00 ET Cathie Wood is a big believer in the genomics revolution. Thanks to the advent of next-generation sequencing, researchers now have access to not only entire genomes in a cost and time-effective manner, but they also have the option of exploring how the expression of t...

2023-07-13 03:27:21 ET Summary Prime Medicine pioneers Prime Editors, a revolutionary gene therapy with broad editing potential, offering high therapeutic impact on diseases by correcting diverse mutations at the genomic level. Prime's Q1 2023 financial report shows increased expe...

-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the...